AVAV's Search Volume Spikes: Trading the SCAR Program News Cycle

The stock's wild swings are a direct reaction to a single, high-stakes news cycle. The core driver is the Space Force's decision to recompete the $1.4 billion SCAR program, a move that sent shares plunging 17% yesterday. The news cycle is now defined by the intensity of search interest around terms like "Space Force SCAR rebidding" or "AVAV contract." This creates extreme headline risk, where the stock's direction is dictated by the next piece of official communication.

The volatility pattern is textbook. The initial announcement triggered a massive sell-off, with analysts like Raymond James downgrading the stock and warning the rebidding could erase up to $1.4 billion from the company's backlog. Yet the stock bounced 6.5% today on a simple statement that it remains in active negotiations with the Space Force for a contract amendment. This back-and-forth mirrors the search volume itself-sharp spikes in interest following each major development, then a drop-off until the next catalyst.

The setup is clear: the stock is trading the day's hottest financial headline. For now, the main character is the SCAR program. The company's confidence in its ability to deliver systems ahead of competitors is a narrative point, but the market's focus is purely on the contract's fate. The upcoming earnings call on March 10th will be the next major data point, but until then, every whisper of progress or setback in the rebidding process will dictate the stock's path.

The Financial Impact: A $1.4 Billion Backlog at Stake

The SCAR rebidding isn't just a headline; it's a direct threat to the company's financial foundation. The program represents approximately $1.4 billion of value, which analysts warn could erase $1 billion to $1.4 billion from AeroVironment's $2.8 billion total backlog if lost. This is the company's largest program of record, making it a critical component of near-term growth visibility. Losing it would cut the company's backlog in half, severely compressing the revenue pipeline for the next several years.

The Pentagon's push to diversify suppliers is the structural reason behind the rebidding. The Space Force is explicitly looking to introduce other vendors into the mix to strengthen manufacturing and supply chain resiliency. This reflects a broader trend away from cost-plus, bespoke contracts toward more competitive, commercialized deals. For AVAV, this means the company's long-standing relationship with the program is now under scrutiny, and its ability to win the next phase will depend on its commercial offering and pricing, not just its technical pedigree.

The financial severity is underscored by the contract's status. The original deal was a flexible Other Transaction Agreement that evolved into a cost-plus development arrangement. The government has now paused the work, and the company is in active negotiations for a contract amendment to move to a firm-fixed-price model. This shift from a potentially open-ended cost-plus contract to a fixed-price deal is a major change in risk and reward, placing more of the cost burden on AVAV. The company is investing in expanded manufacturing capacity to support growth, but that investment now faces uncertainty over whether the SCAR program will materialize at all.

The bottom line is that the SCAR program's fate is a binary event for the company's near-term financial trajectory. The potential revenue exposure is massive, and the rebidding is a tangible catalyst that could erase a decade's worth of backlog growth in a single decision. This is why the stock's volatility is so extreme-the market is pricing in the probability of a catastrophic loss to its financial model.

Counter-Narrative: New Orders and Manufacturing Push

While the SCAR program dominates the news cycle, the company is actively building a counter-narrative through new contracts and capacity investments. In late February, AV secured an $186 million delivery order from the U.S. Army for its next-generation Switchblade loitering munitions. This marks the Army's first procurement of the upgraded line, a tangible win that reinforces the company's role in supplying advanced precision munitions. It's a direct, positive operational catalyst that provides a new search volume driver-terms like "Switchblade 600 Block 2 order" or "Army loitering munitions contract" could start trending as investors look for alternative growth stories.

The company is also betting big on its ability to scale. It is actively investing in expanding manufacturing capacity in Albuquerque, New Mexico to support growth in its Space and Directed Energy platforms. This push is explicitly tied to the SCAR program, but it also signals confidence in broader future demand. The narrative here is about execution and commercialization: AV is building the factories to deliver systems ahead of competitors, which is a key differentiator in a market where the government is pushing for more fixed-price, commercial deals.

Analyst sentiment still reflects this dual view. Despite the SCAR turmoil, Piper Sandler recently lowered its price target from $391 to $290, implying 39% upside. That target is based on the company's long-term potential, not the near-term SCAR outcome. The firm's "overweight" rating acknowledges the operational wins and manufacturing push as reasons to believe in the story, even as it grapples with the immediate contract risk.

The bottom line is that AV is trying to trade two stories at once. The SCAR program is the viral sentiment, the main character of the day's news. But the $186 million Switchblade order and the manufacturing expansion are the counter-narrative, offering alternative search volume drivers and a path to growth if the SCAR deal falls through. For now, the market's attention is fixed on the headline risk, but these operational wins provide a floor for the investment thesis and a potential source of relief if the SCAR uncertainty drags on.

Catalysts and What to Watch

The stock's volatile ride hinges on a few clear, near-term events. The main character for the next few weeks is the resolution of the SCAR contract negotiations. The company's statement that it is in active negotiations with the Space Force on a firm-fixed-price contract is the current narrative. A successful agreement would be a major relief, likely stabilizing the stock and providing a clear path forward. The market will watch for any official announcement of the rebidding process timeline or the selection of new contractors, which would be a major search volume spike and a definitive catalyst.

The next major data point is the company's Q4 earnings report on March 10th. This call will provide updated backlog figures and management commentary on the SCAR situation. The numbers will offer a clearer picture of the financial impact and help investors assess the severity of the potential loss. Given the earlier downgrade and the $1.4 billion value at stake, this report is critical for setting the tone for the rest of the year.

Beyond the SCAR drama, watch for any news on the $186 million Army Switchblade order or the progress of the manufacturing expansion in Albuquerque. These are the counter-narrative catalysts that could provide alternative search volume drivers and support the stock if the SCAR uncertainty drags on. For now, however, the entire market attention is fixed on the contract amendment. The stock will continue to trade the day's hottest headline until that story finds resolution.